JP2022545196A - 抗ｔｃｒデルタ可変１抗体の治療的使用 - Google Patents

抗ｔｃｒデルタ可変１抗体の治療的使用 Download PDF

Info

Publication number
JP2022545196A
JP2022545196A JP2022509647A JP2022509647A JP2022545196A JP 2022545196 A JP2022545196 A JP 2022545196A JP 2022509647 A JP2022509647 A JP 2022509647A JP 2022509647 A JP2022509647 A JP 2022509647A JP 2022545196 A JP2022545196 A JP 2022545196A
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
fragment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022509647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545196A5 (enExample
Inventor
ナタリー マウント
オクサーナ ポリヤコバ
ロバート グッド
マーク ウーデン
ラージ ジェイスクラル メフタ
オリバー ヌスバウマー
Original Assignee
ガンマデルタ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1911799.3A external-priority patent/GB201911799D0/en
Priority claimed from GBGB2010760.3A external-priority patent/GB202010760D0/en
Application filed by ガンマデルタ セラピューティクス リミテッド filed Critical ガンマデルタ セラピューティクス リミテッド
Publication of JP2022545196A publication Critical patent/JP2022545196A/ja
Publication of JP2022545196A5 publication Critical patent/JP2022545196A5/ja
Priority to JP2025113769A priority Critical patent/JP2025160218A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022509647A 2019-08-16 2020-08-14 抗ｔｃｒデルタ可変１抗体の治療的使用 Pending JP2022545196A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113769A JP2025160218A (ja) 2019-08-16 2025-07-04 抗ｔｃｒデルタ可変１抗体の治療的使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1911799.3 2019-08-16
GBGB1911799.3A GB201911799D0 (en) 2019-08-16 2019-08-16 Novel Antibodies
GBGB2010760.3A GB202010760D0 (en) 2020-07-13 2020-07-13 Novel antibodies
GB2010760.3 2020-07-13
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113769A Division JP2025160218A (ja) 2019-08-16 2025-07-04 抗ｔｃｒデルタ可変１抗体の治療的使用

Publications (2)

Publication Number Publication Date
JP2022545196A true JP2022545196A (ja) 2022-10-26
JP2022545196A5 JP2022545196A5 (enExample) 2023-08-21

Family

ID=72148174

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022509647A Pending JP2022545196A (ja) 2019-08-16 2020-08-14 抗ｔｃｒデルタ可変１抗体の治療的使用
JP2022509648A Pending JP2022544683A (ja) 2019-08-16 2020-08-14 新規な抗ｔｃｒデルタ可変１抗体
JP2025113769A Pending JP2025160218A (ja) 2019-08-16 2025-07-04 抗ｔｃｒデルタ可変１抗体の治療的使用
JP2025152149A Pending JP2026009903A (ja) 2019-08-16 2025-09-12 新規な抗ｔｃｒデルタ可変１抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022509648A Pending JP2022544683A (ja) 2019-08-16 2020-08-14 新規な抗ｔｃｒデルタ可変１抗体
JP2025113769A Pending JP2025160218A (ja) 2019-08-16 2025-07-04 抗ｔｃｒデルタ可変１抗体の治療的使用
JP2025152149A Pending JP2026009903A (ja) 2019-08-16 2025-09-12 新規な抗ｔｃｒデルタ可変１抗体

Country Status (13)

Country Link
US (1) US20220403025A1 (enExample)
EP (2) EP4013505A1 (enExample)
JP (4) JP2022545196A (enExample)
KR (2) KR20220084019A (enExample)
CN (2) CN114222585A (enExample)
AU (4) AU2020332878B2 (enExample)
BR (1) BR112022002837A2 (enExample)
CA (2) CA3145517A1 (enExample)
CL (2) CL2022000368A1 (enExample)
CO (1) CO2022002001A2 (enExample)
IL (1) IL290537A (enExample)
MX (1) MX2022002075A (enExample)
WO (2) WO2021032960A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用ＣＤ１ｄ免疫グロブリン
CA3127103A1 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
ES2943063T5 (en) * 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체
EP4147716A1 (en) * 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN121752599A (zh) * 2023-08-31 2026-03-27 南京传奇生物科技有限公司 抗γδTCR抗体及其用途
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
US20260152558A1 (en) 2024-11-27 2026-06-04 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535292A (ja) * 2014-11-17 2017-11-30 アディセット バイオ， インコーポレイテッド 改変γδＴ細胞
US20190144540A1 (en) * 2018-01-23 2019-05-16 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2019519210A (ja) * 2016-05-12 2019-07-11 アディセット バイオ， インコーポレイテッド γδＴ細胞集団の選択的増殖方法及びその組成物
JP2022544683A (ja) * 2019-08-16 2022-10-20 ガンマデルタ セラピューティクス リミテッド 新規な抗ｔｃｒデルタ可変１抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． ＴＣＲγδ＋Ｔ細胞の生産方法
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
PE20190115A1 (es) * 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535292A (ja) * 2014-11-17 2017-11-30 アディセット バイオ， インコーポレイテッド 改変γδＴ細胞
JP2019519210A (ja) * 2016-05-12 2019-07-11 アディセット バイオ， インコーポレイテッド γδＴ細胞集団の選択的増殖方法及びその組成物
US20190144540A1 (en) * 2018-01-23 2019-05-16 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2022544683A (ja) * 2019-08-16 2022-10-20 ガンマデルタ セラピューティクス リミテッド 新規な抗ｔｃｒデルタ可変１抗体

Also Published As

Publication number Publication date
BR112022002837A2 (pt) 2022-05-10
CL2024002250A1 (es) 2024-11-29
MX2022002075A (es) 2022-03-17
WO2021032963A1 (en) 2021-02-25
CN114514245A (zh) 2022-05-17
EP4013505A1 (en) 2022-06-22
AU2020332878B2 (en) 2026-07-30
AU2026205504A1 (en) 2026-07-30
IL290537A (en) 2022-04-01
WO2021032960A1 (en) 2021-02-25
CN114222585A (zh) 2022-03-22
AU2020332878A1 (en) 2022-01-27
AU2020333406B2 (en) 2026-07-30
KR20220084019A (ko) 2022-06-21
AU2026205443A1 (en) 2026-08-06
KR20220084020A (ko) 2022-06-21
CO2022002001A2 (es) 2022-04-08
EP4013504A1 (en) 2022-06-22
AU2020333406A1 (en) 2022-01-27
US20220403025A1 (en) 2022-12-22
JP2026009903A (ja) 2026-01-21
CA3145517A1 (en) 2021-02-25
CA3145523A1 (en) 2021-02-25
JP2022544683A (ja) 2022-10-20
CL2022000368A1 (es) 2022-09-30
JP2025160218A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
JP2025160218A (ja) 抗ｔｃｒデルタ可変１抗体の治療的使用
US20230028110A1 (en) Anti-tcr delta variable 1 antibodies
EP4010082B2 (en) MULTISPECIFIC TCR DELTA VARIABLE DOMAIN 1 ANTIBODIES
HK40097714A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103226A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102396A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103002A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103002B (en) Multispecific anti-tcr delta variable 1 antibodies
HK40103477A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102395A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40102395B (en) Multispecific anti-tcr delta variable 1 antibodies
EA048115B1 (ru) Терапевтическое применение антител к tcr с вариабельной цепью дельта 1
HK40076296A (en) Multispecific anti-tcr delta variable 1 antibodies
HK40076296B (en) Multispecific anti-tcr delta variable 1 antibodies
HK40092859A (en) Multispecific anti-tcr delta variable 1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220218

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220218

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220705

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704